Apellis Pharmaceuticals, Inc. 8-K

What Happened
Apellis Pharmaceuticals (APLS) announced that its Board elected Mikael Dolsten, M.D., Ph.D., as a Class I director effective March 1, 2026 (election approved Feb 27, 2026). Dr. Dolsten will serve until the 2027 Annual Meeting (or until his successor is elected) and has been determined to be “independent” under Nasdaq rules. He was not appointed to any Board committees at the time of the filing.

Key Details

• Dr. Dolsten received equity awards under the Company’s 2017 Stock Incentive Plan totaling $600,000 in grant value at award date: (i) a stock option with a Black‑Scholes value of $300,000 (exercise price = closing stock price on grant date) vesting one‑third each year over three years; and (ii) RSUs with a grant‑date value of $300,000 (number of RSUs = $300,000 ÷ closing stock price) that vest in full on the first anniversary (with an option to defer vesting until after service ends).
• Both the option and RSUs accelerate in full upon a change in control.
• Dr. Dolsten will be paid the same as other non‑employee directors; no family relationships or related‑party transactions were reported.
• He has an indemnification agreement with the Company (form filed previously in the Company’s 2017 registration statement).

Why It Matters
This filing reflects a change in board composition and governance: the Board added an independent, non‑employee director and granted standard director equity compensation totaling $600,000 in value at grant. Investors should note the vesting schedules and change‑in‑control acceleration (which can affect potential dilution and future compensation expense) and that Dr. Dolsten’s compensation follows the Company’s established director pay practices.